The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

“Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation linvoseltamab; the impact of the opinion adopted by the European ...

About the Linvoseltamab Clinical Development ProgramLinvoseltamab ... multicenter Phase 1/2 dose-escalation and dose-expansion LINKER-MM1 trial is investigating linvoseltamab in 282 enrolled ...

"Regeneron's Product Candidates”) and research and clinical programs now underway or planned, including without limitation linvoseltamab; the impact of the opinion adopted by the European Medicines ...

The LINKER-MM1 trial, which enrolled 282 patients with R/R MM, is part of a broader clinical development program exploring the potential of linvoseltamab as both a monotherapy and in combination ...

New data from the phase 1/2 LINKER-M1 trial has shown ... s translational and clinical sciences unit for haematology. “With longer follow-up data on linvoseltamab, we’re seeing deep and ...

Oncology Portfolio: The company's expanding oncology pipeline, including fianlimab (anti-LAG-3 antibody) and linvoseltamab ... Failures in key clinical trials or regulatory setbacks could leave ...